VEGF-trap aflibercept significantly improves long-term graft survival in high-risk corneal transplantation

Transplantation

Volumn 99, Issue 4, 2015, Pages 678-686

  Dohlman, Thomas H ^a   Omoto, Masahiro ^a   Hua, Jing ^a   Stevenson, William ^a   Lee, Sang Mok ^a   Chauhan, Sunil K ^a   Dana, Reza ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; HUMAN MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 3; VEGF C ANTIBODY; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULAR ENDOTHELIAL GROWTH FACTOR C, MOUSE; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CORNEA TRANSPLANTATION; DRUG EFFICACY; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMEANGIOGENESIS; IMMUNOCOMPETENT CELL; LONG TERM SURVIVAL; LYMPHANGIOGENESIS; LYMPHOID TISSUE; MALE; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PEROPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SURGICAL RISK; SURVIVAL TIME; TH1 CELL; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; COMPARATIVE STUDY; DRUG EFFECTS; GRAFT REJECTION; IMMUNOLOGY; METABOLISM; NEUTROPHIL CHEMOTAXIS; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TIME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CHEMOTAXIS, LEUKOCYTE; CORNEAL TRANSPLANTATION; GRAFT REJECTION; GRAFT SURVIVAL; LYMPHANGIOGENESIS; MALE; MICE, INBRED BALB C; MICE, INBRED C57BL; MODELS, ANIMAL; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TH1 CELLS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84930177676     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000512     Document Type: Article

References (66)

1. Lechler RI, Sykes M, Thomson AW, et al. Organ transplantation-how much of the promise has been realized? Nat Med. 2005;11:605.
2. Lakkis FG, Lechler RI. Origin and biology of the allogeneic response. Cold Spring Harb Perspect Med. 2013;3.
3. Dana MR, Qian Y, Hamrah P. Twenty-five-year panorama of corneal immunology: emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection. Cornea. 2000;19:625.
4. Benichou G, Valujskikh A, Heeger PS. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J Immunol 1999; 162:352.
5. Tan Y, Abdulreda MH, Cruz-Guilloty F, et al. Role of T cell recruitment and chemokine-regulated intra-graft T cell motility patterns in corneal allograft rejection. Am J Transplant. 2013;13:1461.
6. He YG, Ross J, Niederkorn JY. Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody. Invest Ophthalmol Vis Sci. 1991;32:2723.
7. Fairchild RL, VanBuskirk AM, Kondo T, et al. Expression of chemokine genes during rejection and long-term acceptance of cardiac allografts. Transplantation. 1997;63:1807.
8. Dastjerdi MH, et al. Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. Invest Ophthalmol Vis Sci. 2010; 51:2411.
9. Hajrasouliha AR, et al. Vascular endothelial growth factor-C promotes alloimmunity by amplifying antigen-presenting cell maturation and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2012;53:1244.
10. Williams KA, Muehlberg SM, Lewis RF, et al. How successful is corneal transplantation? A report from the Australian Corneal Graft Register. Eye (Lond). 1995;9(Pt 2): 219.
11. Niederkorn JY. Immunology and immunomodulation of corneal transplantation. Int Rev Immunol. 2002;21:173.
12. Ing JJ, Ing HH, Nelson LR, et al. Ten-year postoperative results of penetrating keratoplasty. Ophthalmology. 1998;105:1855.
13. Inoue K, Amano S, Oshika T, et al. A 10-year review of penetrating keratoplasty. Jpn J Ophthalmol. 2000;44:139.
14. Maguire MG, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology. 1994;101:1536.
15. Kamp MT, et al. Patient-reported symptoms associated with graft reactions in high-risk patients in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Cornea. 1995;14:43.
16. Olsson A-K, Dimberg A, Kreuger J, et al. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359.
17. Bachmann BO, et al. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol. 2008;126:71.
18. Cursiefen C, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004;45:2666.
19. Albuquerque RJC, et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med. 2009;15:1023.
20. Chen L, et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med 2004;10:813.
21. Dietrich T, et al. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol. 2010;184:535.
22. Zhang H, Grimaldo S, Yuen D, et al. Combined blockade of VEGFR-3 and VLA-1 markedly promotes high-risk corneal transplant survival. Invest Ophthalmol Vis Sci. 2011;52:6529.
23. Sonoda Y, Streilein JW. Orthotopic corneal transplantation in mice-evidence that the immunogenetic rules of rejection do not apply. Transplantation. 1992;54:694.
24. Holz FG, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013;97:278.
25. Brown DM, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155: 429.
26. Boisgérault F, et al. Role of CD4+ and CD8+ T cells in allorecognition: lessons from corneal transplantation. J Immunol. 2001;167:1891.
27. Yamagami S, et al. Cytokine profiles of aqueous humor and graft in orthotopic mouse corneal transplantation. Transplantation. 1998; 66:1504.
28. Niederkorn JY. Immune mechanisms of corneal allograft rejection. Curr Eye Res. 2007;32:1005.
29. Emami-naeini P, Hattori T, Nallasamy N, et al. Poster D932: Soluble VEGFR-3 inhibits lymph-angiogenesis and prolongs corneal graft survival. (2011).http://www.arvo.org/Annual-Meeting/Abstracts/Past-Meeting-Abstract-Search
30. Ristimäki A, Narko K, Enholm B, et al. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem. 1998;273:8413.
31. Cursiefen C, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci USA. 2006;103:11405.
32. Vigl B, et al. Tissue inflammation modulates gene expression of lymphatic endothelial cells and dendritic cell migration in a stimulus-dependent manner. Blood. 2011;118:205.
33. Goldberg MF, Ferguson TA, Pepose JS. Detection of cellular adhesion molecules in inflamed human corneas. Ophthalmology. 1994;101:161.
34. Zhu SN, Dana MR. Expression of cell adhesion molecules on limbal and neovascular endothelium in corneal inflammatory neovascularization. Invest Ophthalmol Vis Sci. 1999;40:1427.
35. Jin Y, et al. The chemokine receptor CCR7 mediates corneal antigenpresenting cell trafficking. Mol Vis. 2007;13:626.
36. Tester A, Phelan D, McColl B, et al. Poster Presentation. VGX-100, a novel therapeutic monoclonal antibody targeting VEGF-C that inhibits tumor growth. American Association for Cancer Research. Washington, DC, USA. Abstract #2442. (2010)http://www.abstractsonline.com/plan/start.aspx?mkey={0591FA3B-AFEF-49D2-8E65-55F41EE8117E}.
37. Mäkinen T, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med. 2001;7:199.
38. Hagura A, et al. The VEGF-C/VEGFR3 signaling pathway contributes to resolving chronic skin inflammation by activating lymphatic vessel function. J Dermatol Sci. 2014;73:135.
39. Huggenberger R, et al. An important role of lymphatic vessel activation in limiting acute inflammation. Blood 2011;117:4667.
40. Kajiya K, Sawane M, Huggenberger R, et al. Activation of the VEGFR-3 pathway by VEGF-C attenuates UVB-induced edema formation and skin inflammation by promoting lymphangiogenesis. J Invest Dermatol. 2009;129:1292.
41. Huggenberger R, et al. Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J Exp Med. 2010;207:2255.
42. Guo R, et al. Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis. Arthritis Rheum. 2009;60:2666.
43. Nissen NN, Polverini PJ, Koch AE, et al. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol. 1998;152:1445.
44. Masuda Y, et al. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol. 2001;159:599.
45. Kim EC, Lee WS, Kim MS. The inhibitory effects of bevacizumab eye drops on NGF expression and corneal wound healing in rats. Invest Ophthalmol Vis Sci. 2010;51:4569.
46. Huq S, Liu Y, Benichou G, et al. Relevance of the direct pathway of sensitization in corneal transplantation is dictated by the graft bed microenvironment. J Immunol. 2004;173:4464.
47. Hua J, et al. Paper presentation: The CCR7-CCL19/CCL21 AxisMediates Enhanced Antigen-Presenting Cell Trafficking In High-Risk Corneal Transplantation. Association for Research in Vision and Ophthalmology. Seattle, WA, USA. Abstract #1289 (2013).http://www.arvo.org/Annual-Meeting/Abstracts/Past-Meeting-Abstract-Search
48. Baldwin ME, Stacker SA, Achen MG.Molecular control of lymphangiogenesis. BioEssays News Rev Mol Cell Dev Biol. 2002;24:1030.
49. Hirakawa S, et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med. 2005;201:1089.
50. Hong Y-K, et al. VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB J. 2004;18:1111.
51. Cao Y, et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA. 1998;95:14389.
52. Rissanen TT, et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res. 2003;92:1098.
53. Joukov V, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15:290.
54. Tammela T, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 2008;454:656.
55. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669.
56. Dellinger MT, Brekken RA. Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium. PLoS One. 2011: 6:e28947.
57. Dellinger MT, Meadows SM, Wynne K, et al. Vascular endothelial growth factor receptor-2 promotes the development of the lymphatic vasculature. PLoS One. 2013;8:e74686.
58. Cursiefen C, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113:1040.
59. Chung E-S, et al. Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands. Am J Pathol. 2009;175:1984.
60. Statement for the Use of Animals in Ophthalmic and Visual Research. athttp://www.arvo.org/About-ARVO/Policies/Statement-for-the-Use-of-Animals-in-Ophthalmic-and-Visual-Research
61. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyeswith corneal neovascularization. Invest Ophthalmol Vis Sci. 1996;37:2485.
62. Cursiefen C, et al. Roles of thrombospondin-1 and ?2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci. 2004;45:1117.
63. Chauhan SK, Saban DR, Dohlman TH, et al. CCL-21 conditioned regulatory T cells induce allotolerance through enhanced homing to lymphoid tissue. J Immunol. 2014;192:817.
64. Holash J, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99:11393.
65. Goyal S, Chauhan SK, Dana R. Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease. Arch Ophthalmol. 2012;130:84.
66. Dohlman TH, et al. The CCR6/CCL20 axis mediates Th17 cellmigration to the ocular surface in dry eye disease. Invest Ophthalmol Vis Sci. 2013;54:4081.